Everything below concerns WADA Prohibited List. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
=== Lifestyle modification === Lifestyle changes have not been shown to reduce the risk of stroke after TIA. While no studies have looked at the optimal diet for secondary prevention of stroke, some observational studies have shown that a Mediterranean diet can reduce stroke risk in patients without cerebrovascular disease. A Mediterranean diet is rich in fruits, vegetables, and whole grains, and limited in red meats and sweets. Vitamin supplementation is not useful in secondary stroke prevention.
There is still disagreement among scientists on Blastocystis hominis's capacity for pathogenicity. Abdominal pain, recurrent diarrhea, and irritable bowel syndrome (IBS) are among the often reported clinical symptoms. The existence of the organism in a large number of asymptomatic people, however, makes it more difficult to comprehend its potential for pathogenicity. Current diagnostic techniques have progressed from basic microscopy to include molecular tools such as PCR-based techniques, since studies have indicated possible links between Blastocystis infections and changes in the gut microbiota.
== History == The concept of hydrogen bonding once was challenging. Linus Pauling credits T. S. Moore and T. F. Winmill with the first mention of the hydrogen bond, in 1912. Moore and Winmill used the hydrogen bond to account for the fact that trimethylammonium hydroxide is a weaker base than tetramethylammonium hydroxide. The description of hydrogen bonding in its better-known setting, water, came some years later, in 1920, from Latimer and Rodebush. In that paper, Latimer and Rodebush cited the work of a fellow scientist at their laboratory, Maurice Loyal Huggins, saying, "Mr. Huggins of this laboratory in some work as yet unpublished, has used the idea of a hydrogen kernel held between two atoms as a theory in regard to certain organic compounds."
=== Column technology === Early gas chromatography used packed columns, made of block 1–5 m long, 1–5 mm diameter, and filled with particles. The resolution of packed columns was improved by the invention of capillary column, in which the stationary phase is coated on the inner wall of the capillary.
In the summer of 1923, the Proletarian Sports Society "Dynamo" was established in Moscow as a sports organization of the Soviet secret police Cheka. On 13 July 1925 the Central Committee of the Russian Communist Party (Bolsheviks) adopted a statement "About the party's tasks in sphere of physical culture". In the statement was determined the role of physical culture in Soviet society and the party's tasks in political leadership of physical culture movement in the country. The Soviet Olympic Committee formed on 21 April 1951, and the IOC recognized the new body in its 45th session. In the same year, when the Soviet representative Konstantin Andrianov became an IOC member, the USSR officially joined the Olympic Movement. The 1952 Summer Olympics in Helsinki thus became first Olympic Games for Soviet athletes. The Soviet Union was the biggest rival to the United States at the Summer Olympics, winning six of its nine appearances at the games and also topping the medal tally at the Winter Olympics six times. The Soviet Union's Olympics success has been attributed to its large investment in sports to demonstrate its superpower image and political influence on a global stage. The Soviet Union national ice hockey team won nearly every world championship and Olympic tournament between 1954 and 1991 and never failed to medal in any International Ice Hockey Federation (IIHF) tournament in which they competed. The Soviet Olympic team was notorious for skirting the edge of amateur rules.
Sources: en.wikipedia.org
The species was named by ornithologist John Latham in 1790 based on a specimen from the Sydney area of Australia, a country which was known as New Holland at the time. He collaborated on Phillip's book and provided the first descriptions of, and names for, many Australian bird species; Dromaius comes from a Greek word meaning "racer" and novaehollandiae is the Latin term for New Holland, so the name can be rendered as "fast-footed New Hollander". In his original 1816 description of the emu, the French ornithologist Louis Pierre Vieillot used two generic names, first Dromiceius and later Dromaius. It has been a point of contention ever since as to which name should be used; the latter is more correctly formed, but the convention in taxonomy is that the first name given to an organism stands, unless it is clearly a typographical error. Most modern publications, including those of the Australian government, use Dromaius, with Dromiceius mentioned as an alternative spelling.
2 oxidized rubredoxin + NADH The 3 substrates of this enzyme are reduced rubredoxin, NAD+, and H+, whereas its two products are oxidized rubredoxin and NADH. This enzyme belongs to the family of oxidoreductases, specifically those acting on iron-sulfur proteins as donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is rubredoxin:NAD+ oxidoreductase. Other names in common use include rubredoxin reductase, rubredoxin-nicotinamide adenine dinucleotide reductase, dihydronicotinamide adenine dinucleotide-rubredoxin reductase, reduced nicotinamide adenine dinucleotide-rubredoxin reductase, NADH-rubredoxin reductase, rubredoxin-NAD reductase, NADH: rubredoxin oxidoreductase, DPNH-rubredoxin reductase, and NADH-rubredoxin oxidoreductase. This enzyme participates in fatty acid metabolism. It has 2 cofactors: FAD and Iron.
== Awards & Sponsorship == In 2011 IBA was granted multiple local innovation awards, e.g. for its Streptamer technology, which allows reversible isolation and staining of antigen-specific T cells. Additionally, a diagnostic test developed by IBA and Fassisi for veterinary diseases was chosen as one of the top five innovations by the county of Göttingen in 2015. Furthermore, the company honors young scientists and participated in research consortia as well.
The chemical nature of GDGTs is succinctly described by its name: they consist of two glycerol molecules connected via two alkyl chains, being held together at four ether linkages. In the living microbe, they are attached to two phosphate head groups that allow them to work as membrane phospholipids. Compared to the typical lipid bilayer in eukaryotes and most bacteria, GDGT-diphosphates differ by having two headgroups, which allow one molecule to do the job of two typical phospholipids (allowing monolayers in water) and resist heat better. They are also connected by ether, instead of ester, bonds. The two primary structural classes of GDGTs are isoprenoid (isoGDGT) and branched (brGDGT), which refer to differences in the carbon skeleton structures.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.